- BioNTech (BNTX, Financial) will announce its Q1 2025 financial results on May 5, accompanied by a conference call and webcast.
- Analysts suggest a potential upside of 19.21% for BioNTech with an average price target of $136.76.
- GuruFocus GF Value indicates a significant downside of 78.73% from the current price of $114.72.
BioNTech (BNTX) is gearing up to disclose its financial performance for the first quarter of 2025 on May 5. To provide a comprehensive overview of its results and strategic direction, the company will host a conference call and webcast starting at 8:00 a.m. EDT. Investors can access details and links on BioNTech's official website, ensuring they don't miss crucial insights from this event.
Wall Street Analysts Forecast
In analyzing the one-year price targets from 19 seasoned analysts, BioNTech SE (BNTX, Financial) demonstrates an average target price of $136.76, with optimistic projections reaching a high of $170.51 and conservative estimates at a low of $109.68. This average target suggests a promising upside potential of 19.21% from the current trading price of $114.72. For investors keen on delving into more detailed projection data, additional insights are available on the BioNTech SE (BNTX) Forecast page.
Considering the recommendations from 21 brokerage firms, BioNTech SE (BNTX, Financial) garners an average brokerage recommendation of 2.0, aligning with an "Outperform" status. With a rating scale spanning from 1 to 5, a 1 indicates a Strong Buy, whereas a 5 suggests a Sell, reflecting a generally favorable sentiment among analysts.
However, GuruFocus presents a contrasting viewpoint with its GF Value estimate for BioNTech SE (BNTX, Financial), which stands at $24.40 for the coming year. This indicates a potential downside of 78.73% from the current trading value of $114.72. The GF Value metric, a cornerstone of GuruFocus analysis, reflects the stock's fair trading value, derived from historical multiples, past business growth, and future performance estimates. For more comprehensive data and analysis, visit the BioNTech SE (BNTX) Summary page.